FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to pharmacology and hematology. Use of the JNK inhibitor (c-Jun N-terminal kinase) as a hemostimulating agent under conditions of cytostatic myelosuppression has been proposed. JNK IQ-IS and SP600125 inhibitors up to 238.2 % and up to 250.2 %, respectively, increased the content of mature neutrophil granulocytes in the bone marrow of mice after cytostatic myelosuppression caused by 5-FU, also increased the erythroid cells content.
EFFECT: invention provides an expansion of the arsenal of highly effective hemostimulating agents.
1 cl, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR STIMULATION OF ERYTHROPOIETIN PRODUCTION BY BONE MARROW CELLS IN VITRO | 2019 |
|
RU2713122C1 |
METHOD FOR STIMULATION OF GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTION BY BONE MARROW CELLS IN VITRO | 2020 |
|
RU2741784C1 |
METHOD FOR STIMULATING PRODUCTION OF GRANULOCYTE COLONY-STIMULATING FACTOR BY BONE MARROW CELLS IN VITRO | 2021 |
|
RU2770784C1 |
HEMOSTIMULATING AGENT | 2013 |
|
RU2514648C1 |
HEMOPROTECTIVE AGENT | 2019 |
|
RU2725135C1 |
HEMOPROTECTIVE AGENT | 2018 |
|
RU2696586C1 |
METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
METHOD FOR STIMULATING MYELOGENESIS | 2010 |
|
RU2442589C1 |
METHOD FOR SIMULATING CHRONIC CYTOSTATIC MYELOSUPPRESSION | 2012 |
|
RU2488890C1 |
HAEMOSTIMULATING AGENT | 2013 |
|
RU2535021C1 |
Authors
Dates
2018-03-19—Published
2017-05-25—Filed